SCHEMBL25439503

SCHEMBL25439503

COC(=O)[C@H]1CCCC[C@@H]1C(=O)Nc1ccc(-c2nnn(C)c2C(=O)O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 1/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HTT P42858 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ POLB P06746 1/20 0.41
▸ FNTA P49354 1/20 0.41
▸ FNTB P49356 1/20 0.41
▸ GAA P10253 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ SLC6A2 P23975 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ ALOX5AP P20292 2/20 0.38
▸ ALOX5 P09917 1/20 0.37
▸ FEN1 P39748 1/20 0.37
▸ PTPN1 P18031 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30472607 0.86 CYP2C19 (0.44) CYP2C19RAB9ALMNAHTTSMN1; SMN2
SCHEMBL30472622 0.84 CYP2C19 (0.42) CYP2C19RAB9ALMNAHTTSMN1; SMN2
SCHEMBL30472667 0.84 CYP2C19 (0.42) CYP2C19RAB9ALMNAHTTSMN1; SMN2
SCHEMBL30472671 0.84 CYP2C19 (0.42) CYP2C19RAB9ALMNAHTTSMN1; SMN2
SCHEMBL25338986 0.79 ALOX5AP (0.37) CYP2C19HTTKDM4EKMT2AMEN1
SCHEMBL31452181 0.78 LPAR1 (0.39) CYP2C19RAB9ALMNAHTTSMN1; SMN2
SCHEMBL25422182 0.73 RAB9A (0.43) CYP2C19RAB9ALMNAHTTSMN1; SMN2
SCHEMBL24867846 0.72 CYP17A1 (0.47) —
SCHEMBL25422589 0.72 CNR1 (0.42) CYP2C19RAB9ALMNAHTTSMN1; SMN2
SCHEMBL30472653 0.71 LPAR1 (0.38) CYP2C19RAB9ALMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066341-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2025-02-27 — — US disclosed
EP-4452965-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-10-30 — — EP disclosed
WO-2023118253-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066341-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS LPAR1, LPAR2, LPAR3 CYP2C19 3844/4885RAB9A 2476/4885LMNA 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback